Vincrisitne
Phase 3Small molecule
AmgenVincrisitne is one of 39 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 3.
2
Indications
1
Total Trials
0
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
408 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Zyloprim
Alnylam PharmaceuticalsPhase 3
Iclusig
TakedaPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Cellcept
RochePhase 3
Arranon
NovartisPhase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Clolar
GGenzyme, a Sanofi Company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vincrisitne. EMBL-EBI & Wellcome Sanger Institute.
- [4]